Amalgamated Bank Sells 285 Shares of Chemed Co. (NYSE:CHE)

Amalgamated Bank cut its holdings in Chemed Co. (NYSE:CHEGet Rating) by 2.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 11,317 shares of the company’s stock after selling 285 shares during the period. Amalgamated Bank’s holdings in Chemed were worth $5,733,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. raised its position in Chemed by 0.5% in the first quarter. BlackRock Inc. now owns 1,350,527 shares of the company’s stock worth $684,111,000 after acquiring an additional 6,546 shares during the period. Kayne Anderson Rudnick Investment Management LLC raised its position in Chemed by 5.2% in the fourth quarter. Kayne Anderson Rudnick Investment Management LLC now owns 487,074 shares of the company’s stock worth $257,682,000 after acquiring an additional 23,949 shares during the period. State Street Corp raised its position in Chemed by 3.3% in the first quarter. State Street Corp now owns 428,845 shares of the company’s stock worth $217,231,000 after acquiring an additional 13,806 shares during the period. William Blair Investment Management LLC raised its position in Chemed by 22.5% in the fourth quarter. William Blair Investment Management LLC now owns 418,761 shares of the company’s stock worth $221,541,000 after acquiring an additional 76,904 shares during the period. Finally, Wellington Management Group LLP raised its position in Chemed by 0.3% in the first quarter. Wellington Management Group LLP now owns 416,960 shares of the company’s stock worth $211,210,000 after acquiring an additional 1,233 shares during the period. 90.42% of the stock is currently owned by institutional investors.

Insider Activity at Chemed

In related news, CEO Kevin J. Mcnamara sold 3,000 shares of the firm’s stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $481.93, for a total transaction of $1,445,790.00. Following the completion of the transaction, the chief executive officer now directly owns 125,185 shares of the company’s stock, valued at $60,330,407.05. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Kevin J. Mcnamara sold 2,000 shares of the firm’s stock in a transaction on Tuesday, September 13th. The shares were sold at an average price of $474.13, for a total transaction of $948,260.00. Following the completion of the transaction, the chief executive officer now directly owns 124,235 shares of the company’s stock, valued at $58,903,540.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Kevin J. Mcnamara sold 3,000 shares of the firm’s stock in a transaction on Thursday, August 18th. The shares were sold at an average price of $481.93, for a total transaction of $1,445,790.00. Following the transaction, the chief executive officer now directly owns 125,185 shares of the company’s stock, valued at $60,330,407.05. The disclosure for this sale can be found here. 4.03% of the stock is currently owned by corporate insiders.

Chemed Stock Performance

Shares of NYSE CHE opened at $480.29 on Monday. The firm has a fifty day moving average price of $485.37 and a 200-day moving average price of $486.17. The company has a debt-to-equity ratio of 0.16, a current ratio of 0.71 and a quick ratio of 0.68. The stock has a market cap of $7.16 billion, a PE ratio of 26.71, a price-to-earnings-growth ratio of 3.61 and a beta of 0.51. Chemed Co. has a 1 year low of $403.00 and a 1 year high of $539.87.

Chemed (NYSE:CHEGet Rating) last announced its quarterly earnings data on Wednesday, July 27th. The company reported $4.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.78 by $0.06. The firm had revenue of $531.29 million during the quarter, compared to analysts’ expectations of $538.07 million. Chemed had a net margin of 12.95% and a return on equity of 44.64%. The company’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the prior year, the company posted $4.60 earnings per share. Equities analysts anticipate that Chemed Co. will post 18.72 earnings per share for the current fiscal year.

Chemed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 2nd. Investors of record on Monday, August 15th were paid a dividend of $0.38 per share. This represents a $1.52 annualized dividend and a yield of 0.32%. This is a boost from Chemed’s previous quarterly dividend of $0.36. The ex-dividend date of this dividend was Friday, August 12th. Chemed’s dividend payout ratio (DPR) is presently 8.45%.

Analysts Set New Price Targets

Separately, Royal Bank of Canada decreased their price target on shares of Chemed from $592.00 to $541.00 and set an “outperform” rating on the stock in a research report on Monday, August 1st.

About Chemed

(Get Rating)

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in two segments, VITAS and Roto-Rooter. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.

Featured Articles

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Co. (NYSE:CHEGet Rating).

Institutional Ownership by Quarter for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.